Literature DB >> 454143

[The frequency of adult anticonvulsant osteomalacia in relation to duration of therapy and dosage of anticonvulsants (author's transl)].

U Mehregan, K H Krause, P Prager.   

Abstract

Of 837 epileptics over 16 years of age treated with mono- or combined hydantoin therapy 20.3% showed radiographic signs of anticonvulsant osteomalacia. With the exception of the patients with severe disturbances of the skeletal system no positive correlation was found with duration of therapy. The percentage of moderate bone changes was the highest in the patients treated for 1 to 2 years; the percentage of severe bone changes in the group treated over 10 years. The rate of osteomalacia correlated with the total dose of hydantoin, phenobarbital, or primidone; the correlation with the dose per year was even more evident. The risk of osteomalacia rose distinctly with doses over 3000 equivalent units/year. The patients with combined hydantoin-barbiturate treatment showed a higher risk than those treated with phenytoin alone. The rate of osteomalacia was the highest in the patients aged under 20 years and over 50 years. Males showed a relatively higher rate of osteomalacia than females, they were treated however with a higher dose per year. The chemical parameters blood alkaline phosphatase and 25-hydroxycholecalciferol corresponded to the radiographic signs, whereas calcium and anorganic phosphate showed no correlation. Early routine radiologic and chemical control especially of the epileptic patients with high risk of osteomalacia should be routinely performed in future.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 454143     DOI: 10.1007/bf00342242

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


  31 in total

Review 1.  [Calcium metabolism disorders in antiepileptic therapy].

Authors:  K Schaefer; D von Herrath; D Kraft
Journal:  Dtsch Med Wochenschr       Date:  1973-05-18       Impact factor: 0.628

2.  Intestinal absorption of vitamin D 3 in epileptic patients and phenobarbital-treated rats.

Authors:  K Schaefer; D Kraft; D von Herrath; A Opitz
Journal:  Epilepsia       Date:  1972-08       Impact factor: 5.864

3.  Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy.

Authors:  E A Sotaniemi; H K Hakkarainen; J A Puranen; R O Lahti
Journal:  Ann Intern Med       Date:  1972-09       Impact factor: 25.391

4.  [Bone structure changes in long-term anticonvulsant treatment].

Authors:  G Berger; B Munde
Journal:  Dtsch Gesundheitsw       Date:  1970-08-13

5.  [Disturbance of ossification in anticonvulsant long-term-treatment (author's transl)].

Authors:  W Stögmann
Journal:  Padiatr Padol       Date:  1971

6.  [Diagnosis of anticonvulsant osteomalacia in adults (author's transl)].

Authors:  K H Krause; P Prager; H Schmidt-Gayk; E Ritz
Journal:  Dtsch Med Wochenschr       Date:  1977-12-23       Impact factor: 0.628

7.  Osteomalacia with long-term anticonvulsant therapy in epilepsy.

Authors:  C E Dent; A Richens; D J Rowe; T C Stamp
Journal:  Br Med J       Date:  1970-10-10

8.  [Handskeleton studies with mammography technique in patients under antiepileptic medication (author's transl)].

Authors:  P J Prager; K H Krause; E Ritz; H Schmidt-Gayk
Journal:  Rofo       Date:  1977-04

9.  Phenobarbital-induced alterations in vitamin D metabolism.

Authors:  T J Hahn; S J Birge; C R Scharp; L V Avioli
Journal:  J Clin Invest       Date:  1972-04       Impact factor: 14.808

10.  Altered calcium metabolism in epileptic children on anticonvulsants.

Authors:  J Hunter; J D Maxwell; D A Stewart; V Parsons; R Williams
Journal:  Br Med J       Date:  1971-10-23
View more
  2 in total

1.  [Reduction of biotin level as a possible factor in the mode of action of anticonvulsants (author's transl)].

Authors:  K H Krause; P Berlit; J P Bonjour
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

Review 2.  Antiepileptic drug toxicity: definition and mechanism of action.

Authors:  E Beghi; R Di Mascio
Journal:  Ital J Neurol Sci       Date:  1986-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.